◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Idorsia Ltd (IDIA) Financial History

Name: Idorsia Ltd (IDIA) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-08-16

Idorsia Ltd (IDIA) operates in the Biotechnology industry and is headquartered in Allschwil, Switzerland with about 424 employees. Its market capitalization is roughly CHF 2 billion. In the fiscal year ended 2025-12-31, IDIA reported CHF 221M in revenue and (CHF 112M) in net income.

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada.

Interactive charts & full statements →

IDIA Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Total Revenue	CHF 221M	CHF 112M	CHF 152M	CHF 97M
Gross Profit	CHF 200M	CHF 77M	CHF 145M	CHF 91M
Operating Income (EBIT)	(CHF 116M)	(CHF 337M)	(CHF 543M)	(CHF 803M)
Net Income	(CHF 112M)	(CHF 264M)	(CHF 298M)	(CHF 828M)

CHF; CHFM / CHFB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IDIA Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31
Total Revenue	CHF 53M	CHF 57M	CHF 48M	—	CHF 72M	CHF 59M	—
Gross Profit	CHF 42M	CHF 49M	CHF 39M	—	CHF 69M	CHF 56M	—
Operating Income (EBIT)	(CHF 36M)	(CHF 26M)	(CHF 52M)	—	(CHF 2M)	(CHF 22M)	—
Net Income	(CHF 107M)	(CHF 46M)	(CHF 78M)	—	(CHF 11M)	CHF 63M	—

CHF; CHFM / CHFB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IDIA Free Cash Flow History

IDIA Balance Sheet History

Balance sheet	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Assets	CHF 466M	CHF 506M	CHF 500M	CHF 904M	—
Total Liabilities	CHF 1.6B	CHF 1.7B	CHF 1.5B	CHF 1.6B	—

CHF; CHFM / CHFB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive IDIA viewer.

Other Companies in Biotechnology

NANO · Nanobiotix S.A. — $2 billion
TRAX · First Tracks Biotherapeutics, Inc. — $2 billion
BCAX · Bicara Therapeutics Inc. — $2 billion
FBRX · Forte Biosciences, Inc. — $2 billion
LKFT · LAKEFRONT BIOTHERAPEUTICS — $2 billion
LBRX · LB Pharmaceuticals Inc — $2 billion
NTLA · Intellia Therapeutics, Inc. — $2 billion
MAZE · Maze Therapeutics, Inc. — $2 billion

← IDHC All “I” companies IDIP →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.